Home » Posts tagged 'POLB'
Tag Archives: POLB
Alan Green provides a SoTP valuation for Power Metal Resources #POW & covers Poolbeg Pharma #POLB on this week’s Stockbox Research Talks
Alan Green provides a SoTP valuation for Power Metal Resources #POW & covers Poolbeg Pharma #POLB on this week’s Stockbox Research Talks
Link here to view the comparison valuation table: POW_SOPTValuation_050323
New Vox Markets Podcast with our CEO Alan Green out now
New Vox Markets Podcast #podcast with our CEO Alan Green discussing:
– Poolbegb Pharma #POLB
– Amryt Pharma (Nasdaq: #AMYT)
– Georgia Capital #CGEO
– Marula Mining #MARU
https://www.voxmarkets.co.uk/articles/alan-green-talks-about-poolbeg-pharma-georgia-capital-marula-mining-b8602ad/
Poolbeg Pharma #POLB – POLB 001 LPS human challenge clinical trial successfully completed & no serious adverse events reported.
12 December 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that, further to its announcement in July 2022, it has now received the initial results having completed the Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza.
Key highlights from the study:
· No further clinical activity is required to complete the objectives of the trial, bringing the recruitment and clinical phase to a close on schedule
· No serious adverse events reported. POLB 001 was found to be safe and well tolerated
· Data analysis has commenced and full data read-out is expected in Q2 2023
· The comprehensive dataset is expected to facilitate progression of the product to the next clinical phase for potential partners
This LPS challenge trial was designed to evaluate the effect of POLB 001 on inflammatory responses in 36 healthy volunteers between 18 and 55 years of age following an intradermal and an intravenous LPS challenge. LPS acts as a surrogate for the hyperinflammatory response associated with severe influenza and other diseases.
POLB 001 is a unique potential treatment for viruses such as severe influenza as it is strain agnostic, unlike other flu treatments and prophylactics. This means that it can be effective regardless of which strain of influenza is dominant in any particular season or geography. As a shelf-stable, oral drug it could also be ideal as a stockpiling candidate for both seasonal outbreaks and pandemic preparedness.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“We have completed our first trial on schedule, achieving a key milestone for Poolbeg, thanks to the committed efforts of the team. We are actively planning the next steps for POLB 001 and are engaging with industry on potential partnering opportunities.
“The threat of influenza shouldn’t be underestimated. Cases are on the rise – the WHO estimates that there are 3-5 million severe influenza cases globally per year, with real pandemic potential. Severe influenza can also lead to other major complications such as pneumonia and stroke. There is a significant unmet need for severe influenza treatments, so we eagerly anticipate the full results of this study next year.”
Matthijs Moerland, PhD, Principal Investigator at CHDR, said:
“LPS human challenge trials are a highly reliable way of measuring the efficacy of anti-inflammatory drugs and these initial data are an important first step. We are pleased to be involved in the development of a potential treatment for such an unmet need as severe influenza and we look forward to the vital insights that the full analysis will bring.”
-Ends-
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+44 (0) 207 183 1499 |
|
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)
|
+44 (0) 207 220 0500 |
|
Singer Capital Markets (Joint Broker) Phil Davies, Sam Butcher
|
+44 (0) 207 496 3000 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Optimum Strategic Communications Mary Clark, Nick Bastin, Manel Mateus, Vici Rabbetts
|
+44 (0) 208 078 4357 poolbeg@optimumcomms.com |
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in prevalent and emerging infectious diseases. Poolbeg has a disciplined portfolio approach to mitigate risk, accelerate drug development and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, and in-license near or in the clinic medicines, leading to faster development and greater commercial appeal.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.
With its initial assets from hVIVO plc (formerly Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) which has completed its LPS human challenge trial with full data read-out expected in Q2 2023; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing an Oral Vaccine Platform and is progressing two Artificial Intelligence (AI) Programmes to accelerate the power of its human challenge model data and biobank, with results from the first programme expected by year end.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
Further detail on POLB 001
This trial is a randomised, double-blind, placebo-controlled, multiple dose, LPS human challenge trial in 36 healthy volunteers to assess the potential efficacy of POLB 001 in treating the hyperinflammatory responses associated with severe influenza. As part of the trial, researchers stimulated the immune systems of healthy volunteers with LPS across three cohorts. LPS triggers a robust immune response and acts as a surrogate for the hyperinflammatory effects associated with severe influenza infection, as well as other diseases. Each cohort received escalating doses of POLB 001 to evaluate its effectiveness in suppressing the body’s harmful inflammatory response to both intradermal (a shallow injection) and intravenous (an injection in a vein) administered LPS, which will produce a broad-ranging dataset.
Given POLB 001’s mode of action, it is viral strain agnostic as it treats the body’s reaction to infection rather than targeting the virus directly and, as such, POLB 001 is unaffected by the seasonal variants of influenza that arise each year which is a significant advantage over influenza treatments available on the market. Therefore, POLB 001 has the potential to be a transformational treatment for patients and to become a leading severe influenza treatment. POLB 001 has patent protection until 2038 and is a shelf-stable oral drug which makes it ideal as a stockpiling candidate for both seasonal outbreaks and pandemic preparedness.
POLB 001 also has potential therapeutic applications beyond severe influenza, due to its mode of action of reducing hyperinflammation (cytokine storm). This is when harmful inflammation occurs in different areas of the body, such as the heart and lungs, causing organ damage which is linked with many diseases. POLB 001 has the potential to block this by interrupting the positive feedback loop of inflammatory mediators. Poolbeg is currently investigating new potential uses and in due course hopes to expand its IP around this asset to cover new disease areas thereby increasing the value of the asset.
The data collected in the previous Phase I study demonstrated that POLB 001 administration produces a potent and long-lasting inhibition of p38 MAP Kinase activity in humans. The study showed that after administration of single doses up to 600 mg and repeated doses up to 150 mg there were neither serious nor limiting adverse events to POLB 001, and that after a twice daily dose of 150mg an inhibition of LPS-induced TNFα of between 70% and 90% was achieved.
About Influenza
Influenza is a viral pathogen that infects approximately one-eighth of the world’s population each year, an estimated 1 billion people infected globally, attacking the respiratory system leading to between 5 and 10 million hospitalisations and as many as 500,000 influenza related deaths. Survivors of severe influenza can suffer organ damage, leading to chronic and life-changing injuries. Complications include a 6-fold increased risk of heart attack, an 8-fold increased risk of Pneumonia, and an 8-fold increased risk of stroke. This leads to an enormous compound cost of treatment – influenza contributes to an estimated economic burden of $11.2bn every year in the US alone
Poolbeg Pharma #POLB – Influenza Artificial Intelligence model build completed & on track to deliver outputs in Q2 2023
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that, further to its announcement in March 2022 , the construction of the computational artificial intelligence (AI) influenza disease model has been completed by CytoReason Limited (‘CytoReason’), indicating that it is on track to deliver outputs in Q2 2023.
The model aims to unlock clinically meaningful insights into influenza infection and recovery through the analysis of Poolbeg’s unique human challenge trial data. CytoReason has now built a tailored AI model using Poolbeg’s data which will allow the team to identify novel influenza drug targets for Poolbeg.
CytoReason’s technologies are externally validated through its commercial partnerships with five of the world’s top ten global pharma companies accessing its world-leading AI models, including Pfizer, Roche, and Sanofi. CytoReason’s application of Poolbeg’s unique human challenge trial data to build and train its first AI model in infectious diseases further testifies to the value of this data.
CytoReason’s world leading algorithms and experts will enable the Poolbeg team to identify the most promising drug targets to treat disease. The Company plans to source drugs with existing Phase I safety data that, in line with the Poolbeg business model, can immediately continue clinical development to rapidly generate early human proof of concept data for influenza, with the ultimate aim of monetising the asset through partnerships and licensing deals with pharma and biotech.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“CytoReason builds world-class AI disease models and we look forward with great anticipation to the outputs from their analysis of our unique repository of clinical samples and associated data from influenza human challenge trials. Indeed this is the first time that AI is being used to analyse influenza human challenge trial data which Poolbeg is proud to be part of.”
“Completion of this first stage of development demonstrates yet another milestone reached in the Company’s stated R&D strategy and brings us one step closer to realising the significant opportunities that arise from this partnership. There is a growing focus on AI discovered drug targets within the industry and we are assessing interest in collaboration opportunities for our AI-enabled novel targets which we expect in Q2 2023 from this programme. “
David Harel, CEO of CytoReason, said:
“Now that our influenza disease model has been enriched by Poolbeg’s unparalleled data, we are excited to evaluate the novel disease mechanisms on our platform. This will potentially identify drug targets that can be used to develop treatments for influenza, a significant global health threat, in a much shorter time-frame and more cost effectively than with traditional reductionist analysis and drug discovery techniques.”
-Ends-
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+44 (0) 207 183 1499 |
|
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)
|
+44 (0) 207 220 0500 |
|
Singer Capital Markets (Joint Broker) Phil Davies, Sam Butcher
|
+44 (0) 207 496 3000 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field, Adam Loudon
|
+44 (0) 20 7457 2020 |
Further detail on Poolbeg’s Artificial Intelligence Programmes
Poolbeg Pharma has access to a unique private repository of clinical samples and associated data from human challenge trials via its relationship with hVIVO plc (formerly Open Orphan plc), a resource which is anticipated to expand over the coming years.Data from human challenge trials are unique in that they track a healthy subject through disease to recovery in carefully controlled and monitored isolation units, collecting samples throughout the course of disease, and vitally collecting matched baseline and follow-up samples before and after infection. This data is unique in the depth of longitudinal virology, health, biomarker and symptom data collected during the course of disease. These datasets provide clinical insights into disease that guides Poolbeg Pharma’s product acquisitions and clinical development.
CytoReason’s machine learning algorithm works by combing through enormous repositories of clinical data to build models of human disease, which can then be used by biotech and pharmaceutical partners to identify novel targets, prioritise mono/combination therapies, find biomarkers, and understand which patients will benefit most from those new treatments. CytoReason will be analysing blood transcriptomics, proteomics, DNA sequences and viral loads and disease signs and symptoms from the human challenge trials. The aim is for CytoReason to prioritise new drug targets quickly and cost effectively, in a manner consistent with Poolbeg’s business model.
The Company is currently progressing two AI Programmes, the first in RSV in partnership with OneThree Biotech , and the second in influenza in partnership with CytoReason . Poolbeg believe that this is the first time that AI analysis has been undertaken on RSV and influenza human challenge trial data and samples to identify new drug targets and treatments. The unique nature of human challenge trials to produce disease progression data with high precision is revolutionising the insights into human disease.
About Influenza
Influenza is a viral pathogen that infects approximately one-eighth of the world’s population each year, an estimated 1 billion people infected globally, attacking the respiratory system leading to between 5 and 10 million hospitalisations and as many as 500,000 influenza related deaths. Survivors of influenza can suffer organ damage, leading to chronic and life-changing injuries. Health organisations have warned that the upcoming influenza season could be especially severe, as a consequence of low immunity to the virus due to the pandemic causing a break in exposure.
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a unique capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for pharma and biotech seeking mid-stage products to license or acquire.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.
With its initial assets from hVIVO plc (formerly named Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) which has commenced its LPS human challenge trial with initial results expected by year end 2022; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) programmes to accelerate the power of its human challenge model data and biobank, with results from the first programme expected by year end 2022.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
About CytoReason
CytoReason is a leading technology company developing computational disease models. The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases – tissue by tissue and cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies can identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval. To date, five of the world’s top ten pharma companies use CytoReason’s technology. For more information, visit www.cytoreason.com or follow us on LinkedIn or Twitter.
Markets and Stocks – Doc Holliday talks to Alan Green
As we head towards Christmas, Alan Green and Doc Holliday talk markets and stocks. We discuss the macro events in the UK and the opportunities that Brexit and inflation could be throwing up for UK agriculture before we turn to stocks. Doc covers Harland & Wolff #HARL, ECR Minerals #ECR, Contango Holdings #CGO, Emmerson #EML, Longboat Energy #LBE, Poolbeg Pharma #POLB, hVIVO #HVO, Reabold Resources #RBD and More Acquisitions #TMOR.
Quoted Micro 21 November 2022
AQUIS STOCK EXCHANGE
EDX Medical (EDX) completed its reversal into shell TECC Capital in a deal valued at £12m and £1.2m was raised at 6p a share. The share price returned from suspension and increased by 64.1% to 5.25p, but it is still below the placing price. EDX Medical develops digital diagnostic products and service for cancer, heart disease, neurology and infectious diseases.
Non-fungible token platform developer Looking Glass Labs Ltd (NFTX) has been introduced to the Access segment of Aquis on 14 November. Web 3.0 Holdings Ltd was acquired prior to the flotation. This is a Web3 technology company that owns a retail technology platform. The company’s brand House of Kibaa has designed a next generation metaverse for 3D assets. This enables functional art and collectibles to exist across different NFT blockchains. Sales of digital assets have totalled C$6.2m and there is a 5% royalty stream on secondary sales. There were early deals at 17p a share and the share price has fallen to 13.5p.
Oscillate (MUSH) is planning to acquire Hi55 Ventures Ltd, a fintech platform designed to help companies with payroll flexibility. Trading in the shares was suspended at 0.75p each. The share-based deal values Hi55 at £28m at a notional share price of 1.29p. Existing Oscillate shareholders will be given a warrant exercisable at 1.29p for each share they own. Hi55 allows employees to access their salary as they earn it. This finance can be delivered in partnership with MasterCard.
Vulcan Industries (VULC) has not been able to conclude the proposed agreement to acquire Peregrine X Ltd. Discussion continue so a different structure to the deal might be possible. Vulcan Industries continues to sell its other interests. Components manufacturer Tim Rainham has been sold for £1. The business had net liabilities. Earlier this month, raised £157,000 in a placing at 8.2p a share.
Quetzal Capital (QTZ) says that proposed acquisition target Tap Global has no direct exposure to the defunct cryptocurrency company FTX.
Watchstone Group (WTG) has agreed settlement terms with former auditor KPMG. The final payment is £4.95m. Net assets were £11.4m at the end of June 2022, which was mainly cash. The share price increased by 11.5% to 29p, which values Watchstone at £12m.
Tectonic Gold (TTAU) has recommenced drilling at the Specimen Hill project in Queensland. This is drilling below a previous mine and one result was 8.17g/t gold over one metre in distal veins. A shortage of drilling rigs delayed the restart. The drilling should be completed in a fortnight.
Wishbone Gold (WSBN) has exercised its option to acquire the Anketell gold-copper project in Western Australia. This cost £320,000 in shares at 14.75p a share and £50,000 in cash.
Web3 gaming and infrastructure company Pioneer Media Holdings Inc (PNER) has closed the first tranche of the previously announced placing, and this raised C$580,000 at C$0.10 a unit – one share and 0.5 of a warrant exercisable at C$0.25. This is a huge discount to the market price. The share price slumped 14.3% to 30p. This cash will finance technology development and working capital. Olivia Edwards has been appointed to the board.
Diesel additives supplier SulNOx Group (SNOX) has secured an order in South Africa and a repeat order in Costa Rica. Agriculture has proved to be a large customer base.
Aquaculture and geotracking technology developer OTAQ (OTAQ) increased interim revenues by 11% to £2.03m and the reported loss fell from £881,000 to £538,000. The cash raised when OTAQ moved to Aquis will finance further technology investment. Management says that there will be a period of adjustment. Nigel Wray increased his stake from 15.8% to 19.35%.
IamFire (FIRE) is raising £3.5m at 2.5p a share.
BWA Group (BWA) has £7,367 of cash and net liabilities of £168,000. It is seeking to raise more cash.
Marula Mining (MARU) has increased its fundraising to £519,500 at 2p a share. Richard Lloyd withdrew himself from re-election as a director.
AIM
Totally (TLY) reported further progress in its latest interims with trading generally back to pre-lockdown levels. Demand for insourcing of operations has grown significantly and used up more working capital. Revenues grew but underlying pre-tax profit was flat at £2m. However, earnings fell because of a higher tax charge. Contracts worth £37m were extended. Underlying full year pre-tax profit is expected to improve from £3.7m to £5.7m, helped by insourcing demand as the NHS tries to reduce waiting lists.
Delays in commencing manufacturing and building up sales of Stereax small battery cells have knocked the Ilika (IKA) share price, which slumped 34.7% to 32p. The commercial prototypes will not be available until the end of 2023. It is also taking longer than anticipated for the larger Goliath batteries to reach the position where they have equivalence with lithium-ion cells. Forecast group revenues have been cut for this year and next year, while the 2024-25 forecast has been slashed from £18.1m to £2.7m by Berenberg. That indicates the length of the delays. That would put Ilika into a net debt position.
Wynnstay Group (WYN) is acquiring Cornwall-based feed supplier Tamar Milling for an initial £1.4m. This is immediately earnings enhancing. In 2020-21, Tamar Milling revenues were £6.4m and pre-tax profit of £420,000. Wynnstay says that its 2021-22 results will be better than expected. Grain, seed and fertiliser revenues have been strong and joint venture businesses will make a higher than expected profit contribution. There is also a boost in the figures from the accounting treatment of the hedging of wheat contracts.
Chain and transmission equipment manufacturer Renold (RNO) continues to trade well in tough times. Interim revenues were 22% ahead at £116.3m, while underlying pre-tax profit was two-fifths higher at £7.3m. The acquisition of Industrias YUK in Spain meant that net debt increased to £34m, but management is still confident that it can finance further acquisitions when they are identified. Higher interest rates have helped to reduce the net pension deficit by one-quarter to £56.6m. The order book is worth £99m, which is a record.
Digital coupons and loyalty technology provider Eagle Eye (EYE) is acquiring France-based Untie Nots, which provides promotion and gamification SaaS products to retailers. The deal will cost up to €38.8m. The initial payment is €9.1m in cash and €5.9m in shares at 555p each. A placing will raise £7m at 555p a share and the rest of the cash will come from existing net cash of £3.6m. The deferred payments of up to €23.8m will depend on achieving revenue targets in 2022, 2023 and 2024, which equate to annual growth of 60%, as well as achievement of a minimum EBITDA margin.
Harland & Wolff (HARL) is involved in Team Resolute, a consortium that is preferred bidder for a £1.6bn contract to build Royal Navy support vessels. This will require significant investment in the Belfast shipyard. The Appledore shipyard in Devon will also be involved.
Poolbeg Pharma (POLB) and consortium partners have been awarded a €2.3m grant by an Irish government fund to develop an oral vaccine candidate from pre-clinical to phase I readiness. The aim is to induce mucosal immunity. The week before Poolbeg identified multiple novel drug targets for the treatment of respiratory syncytial virus (RSV) through it s collaboration with OneThree Biotech.
N4 Pharma (N4P) is raising £1m at 2p a share. A broker offer could raise up to £1m more. The share price slumped by 30.5% to 2.05p. The cash will be used for the development work relating to loading SiRNA onto delivery vehicle Nuvec, plus for funding the investigation of possible acquisitions.
MAIN MARKET
Standard listed BSF Enterprise (BSFA) says that its subsidiary 3d Bio-Tissues has produced three small prototype fillets of cultivated meat, which is a step towards a full-scale cultivated meat fillet. This comes at a time when the US FDA has given approval to a cultivated meat product for the first time. The cultivated meat fillets were 30mm in height and 15mm in diameter and weighed 5 grammes. They were some of the first 100% cultivated meat fillets produced in the world. The comparisons with conventional meat were described as “comprehensively positive”. The first full-scale cultivated meat fillet should be showcased early next year.
Braemar (BMS) increased interim revenues by 46% to £69.4m, helped by the strength of the dollar. Underlying pre-tax profit more than doubled to £10.5m and Braemar moved into a net cash position of £1.8m. The interim dividend was doubled to 4p a share.
Trading continues to improve at Castings (CGS) and interim revenues were 23% higher at £85.6m, while pre-tax profit recovered 38% to £7.5m. Price increases offset cost rises. There is strong demand for HGVs and short-term component order books remain strong. The interim dividend is 3.84p. Net cash is £25.6m and that should rise significantly in the second half.
J Smart Contractors (SMJ) is paying a final dividend of 2.27p a share. In the year to July 2022, revenues fell from £10.4m to £7.43m as construction activity declined. Thanks to a £6.06m profit on the sale of investment properties a pre-tax profit of £8.19m was reported. That is down from £14.9m the previous year, although that included a revaluation surplus of £12.1m. NAV is £124.7m, including net cash of £20.7m.
Standard list Rockpool Acquisitions (ROC) announced heads of terms for the purchase of Amcouri Group, which is a holding company for nine engineering and manufacturing businesses. The potential cost is £22.3m in ordinary shares based on the forecast profit forma EBITDA of £5.4m.
Net Zero Infrastructure (NZI) has terminated acquisition talks with Taylor Construction because it could not raise the cash required for the deal. NAV is £650,000.
Andrew Hore
#POLB Poolbeg Pharma Plc- Capital Markets Day
17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it will be holding a Capital Markets Day for analysts and institutional investors on Wednesday 30 November between 10am – 12:45pm.
The event, which will be chaired by Jeremy Skillington, Chief Executive Officer, will provide insights into a number of the Company’s growing pipeline of infectious disease vaccines and treatments and one of its innovative artificial intelligence programmes which is unlocking the power of human challenge trial data. In addition, attendees will gain a greater understanding of how Poolbeg’s unique model and business development strategy can drive growth from the infectious disease market. A networking lunch will follow at the end of the session.
There will be an opportunity for attendees to take part in a Q&A with Poolbeg’s management team including Ian O’Connell, Chief Financial Officer and David English, VP of Business Development as well as a number of guest speakers:
|
• |
Dr Tal Almog of CytoReason, one of Poolbeg’s artificial intelligence partners; a world leader in AI which to date has worked with five of the world’s top ten pharma companies |
|
• |
Derek Gilroy, Head of the Centre for Clinical Pharmacology and Professor of Immunology at University College London and has pioneered research examining the molecular and biochemical pathways that regulates the resolution of acute immune reactions |
|
• |
Professor Brendan Buckley, co-founder of Minerva Medical, acquired by IQVIA and Firecrest Clinical, acquired by ICON plc where he held the position of Chief Medical Officer. Brendan has over thirty years of experience in clinical research and has published over 150 scientific papers |
|
• |
Further speakers will be announced in advance of the event |
Analysts, institutional investors and media are welcome to attend the event in the City of London. Due to restrictions on numbers, it will not be possible for all interested parties to attend in-person. However, a live webcast will be available for retail investors and others to view the presentations here.
To register your interest to attend the in-person event, please RSVP to poolbeg@instinctif.com.
A recording of the presentation will be made available on the Company’s website after the event here.
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+44 (0) 207 183 1499 |
|
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, Charlie Beeson
|
+44 (0) 207 220 0500 |
|
Singer Capital Markets (Joint Broker) Phil Davies, Sam Butcher
|
+44 (0) 207 496 3000 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field
|
+44 (0) 20 7457 2020 |
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for Big Pharma seeking mid-stage products to license or acquire.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.
With its initial assets from hVIVO plc (formerly named Open Orphan plc), an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) which has commenced its LPS human challenge trial with initial results expected by year end 2022; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) programmes to accelerate the power of its human challenge model data and biobank, with outputs from the first programme expected by year end 2022.
Poolbeg Pharma #POLB – Poolbeg-led consortium awarded EUR 2.3m grant
15 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that ‘EncOVac’, a consortium led by Poolbeg Pharma, has been awarded €2.3m in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s Disruptive Technologies Innovation Fund (‘DTIF’).
Taking place over three years, the collaboration between Poolbeg Pharma, University College Dublin, Trinity College Dublin and AnaBio Technologies will result in the development of an oral vaccine candidate to a Phase I ready state. The resulting technology will serve as a platform for additional oral vaccine candidates for a wide range of pathogens, initially targeting bacterial infections. Poolbeg is proud to play a role in the development of the next generation of vaccine technologies that can protect the world from infectious diseases.
Poolbeg licensed AnaBio’s microencapsulation and nanoencapsulation technologies for use in the development and commercialisation of oral vaccines in January 2022 . By delivering vaccines to the gut, oral vaccines can trigger ‘mucosal immunity’ that results in a protective response in the areas of the body where a pathogen would be inhaled or ingested such as the nose and digestive tracts. In comparison to intramuscular injections which generate systemic immunity, this approach prevents infections from taking hold in the body by counteracting them at the point of entry. This has the effect of both reducing transmission and preventing serious disease. Oral vaccines also offer an efficient method of administration and significantly reduce challenges for distribution, addressing the gaps in supplying the global community as well as needle-phobia which factors in vaccine hesitancy.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma said: “We are grateful for the support of the Irish Government in awarding this funding and delighted to be working with our consortium of high-quality partners in University College Dublin, Trinity College Dublin and AnaBio. The funding will support the progression of this exciting oral vaccine platform that has the potential to improve the ways vaccines are manufactured, distributed and administered for the future. Poolbeg continues to target non-dilutive funding opportunities and we are delighted that this DTIF award is our first success.”
Prof Siobhán McClean, Associate Professor at University College Dublin (“UCD”) said: “I am pleased to work with the other members of this consortium to bring the antigens my team have identified and developed, closer to the clinic so that together, we can protect people from infectious diseases.”
Prof Ed Lavelle, Professor of Immunology at Trinity College Dublin (“TCD”) said: “The pharmaceutical industry has long aspired to develop subunit oral vaccines and I believe we have assembled a consortium of experts and ground-breaking technologies that are uniquely placed to make them a reality.”
Dr Sinéad Bleiel, Founder & Chief Scientific Officer of AnaBio Technologies said: “Having demonstrated the potential of our encapsulation technology to deliver drug products safely and effectively to the gut, we are excited to collaborate with the EncOVac team of world class researchers, led by Poolbeg and supported by the Irish Government as part of the world’s renewed fight against infectious diseases.”
Prof Luke O’Neill, Non-Executive Director, Scientific Advisory Board and Project Advisory Board Chair said:“Oral vaccines are currently only available to treat a small number of pathogens and a more comprehensive approach to vaccine development is needed to design new, safe, and effective oral vaccines. Such a system would revolutionise our approach to protecting people from infectious diseases, unleashing their full potential.”
– Ends –
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO
|
+44 (0) 207 183 1499 |
|
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, Charlie Beeson
|
+44 (0) 207 220 0500 |
|
Singer Capital Markets (Joint Broker) Phil Davies, Sam Butcher
|
+44 (0) 207 496 3000 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
|
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field
|
+44 (0) 20 7457 2020 |
Notes to Editors
About EncOVac
Leveraging the pioneering work of Assoc. Professor Siobhán McClean in University College Dublin (“UCD”), the Consortium will use vaccine candidates identified in her lab as the basis for an oral vaccine that is generated through a highly specialized encapsulation process developed by Dr. Sinéad Bleiel of Anabio Technologies. Working with Ed Lavelle, vaccine adjuvant expert and a mucosal immunologist in Trinity College Dublin (“TCD”), the consortium will develop a vaccine candidate through pre-clinical testing to a Phase I ready state. Poolbeg has previously announced an exclusive license with Anabio for the use of their technology in vaccine delivery and has successfully in-licensed onevaccine candidate from UCD and continues to evaluate five other potential vaccine candidates developed by Associate Professor Siobhán McClean and her team.
About Oral Vaccines
By delivering vaccines to the gut, this approach can trigger ‘mucosal immunity’ that results in a protective response in the areas of the body where a pathogen would be inhaled or ingested such as the nose and digestive tracts. In comparison to intramuscular injections which generate systemic immunity, this approach prevents infections from taking hold in the body by counteracting them at the point of entry. This has the effect of both reducing transmission and preventing serious disease. Oral vaccines also offer an efficient method of administration and significantly reduce challenges for distribution, addressing the gaps in supplying the global community as well as needle-phobia which factors in vaccine hesitancy.
A recent World Health Organisation Report (“WHO”) estimated that the global market value for vaccines was approximately $33b in 2019, before the substantial investment arising from the pandemic. The development of an oral vaccine platform that could replace some injectable vaccines would serve to improve vaccination rates, address critical inequalities in distribution and help to create a healthier world.
About the Disruptive Technologies Innovation Fund
The Disruptive Technologies Innovation Fund (DTIF) is a €500 million fund established under the National Development Plan (NDP) in 2018. The Department of Enterprise, Trade and Employment manages the DTIF with administrative support from Enterprise Ireland. The purpose of the Fund is to drive collaboration between Ireland’s world-class research base and industry as well as facilitating enterprises to compete directly for funding in support of the development and adoption of these technologies. The aim is to support investment in the development and deployment of disruptive technologies and applications on a commercial basis.
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a unique capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for pharma and biotech seeking mid-stage products to license or acquire.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.
With its initial assets from hVIVO plc (formerly named Open Orphan plc) , an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) which has commenced its LPS human challenge trial with initial results expected by year end 2022; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) programmes to accelerate the power of its human challenge model data and biobank, with results from the first programme expected by year end 2022.
Poolbeg’s role in the project will be to prepare the vaccine candidate for clinical approval, including the preparation of pre-clinical toxicology work and the preparation of a regulatory dossiers for submission to the relevant authorities prior to the initiation of clinical trials. In addition to these activities, as the consortium-lead, Poolbeg will be responsible for project management, intellectual property protection and the coordination of publicity
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
About AnaBio Technologies
AnaBio Technologies is a specialist microencapsulation company, focused on improving health and performance through micro-encapsulation of sensitive bioactive ingredients for food, beverage and pharmaceutical applications. Founded in 2011 by Dr Sinead Bleiel, and based in Carrigtwohill Co Cork, AnaBio has developed into a global leader in the field of micro encapsulation with 15 patent families and clients across N America, Asia, and EU.
Bioactives and APIs clearly bestow health benefits, but are vulnerable to being inactivated by environmental stresses encountered during processing, storage and digestion. This can result in limited quantities of intact active bioactives reaching the site of action in the body, and no health benefit.
Microencapsulation represents a sophisticated delivery system designed to overcome this problem. A protective coat is created at microscopic level around the bioactive or API which protects the ingredient from a wide range of environmental conditions, enables its release at the appropriate site within the body, and thereby ensures that the potential health benefits of the bioactive are fully realised. AnaBio Technologies offers its clients a range of services including contract research to develop bespoke microencapsulation solutions, commercial scale manufacture and supply of microencapsulated ingredients and licensing of its patented microencapsulated technology.
As part of the project, Anabio will be responsible for the encapsulation of the vaccine antigen and adjuvant combination. This will protect vaccine antigens from the degradative environment of the digestive tract and deliver vaccine constituents via a triggered release of microcapsule dissolution at a specific pH, which is characteristic to the location of the intestine where antigen uptake is targeted.
For further information, visit www.anabio.ie or email aidan.fitzsimons@anabio.ie .
About University College Dublin (“UCD”)
UCD is Ireland’s largest and most diverse university and one of Europe’s leading research-intensive universities. Since 1854 UCD has made a unique contribution to the creation of modern Ireland, based on successful engagement with Irish society on every level and across every sphere of activity. As Ireland’s leading university in innovation, knowledge transfer and commercialisation, UCD’s commitment to innovation and entrepreneurship recognises the importance of active participation and collaboration to exploit leading-edge research and development outputs. As set-out in Rising to the Future 2020-2024 UCD’s four strategic themes are; creating a sustainable global society, transforming through digital technology, building a healthy world, and empowering humanity.
To further expand the diseases the oral vaccine platform can target, the team in UCD will characterise and prioritise additional vaccines candidates using the proteomic platform technology previously developed by the McClean lab. Once a preferred candidate is identified, its efficacy following encapsulation will be assessed in an animal challenge model.
For further information, visit www.ucd.ie
About Trinity College Dublin (“TCD”)
Trinity College Dublin, founded in 1592, is Ireland’s oldest university. Today it has a vibrant community of over 20,000 students and is recognised internationally as Ireland’s premier university, currently 98th in the QS University World Rankings. Cutting edge research, technology and innovation places the university at the forefront of higher education in Ireland and globally. It encompasses all major academic disciplines, and is committed to world-class teaching and research across a range of disciplines in the arts, humanities, engineering, science, social and health sciences. Trinity is Europe’s leading university for graduate entrepreneurship and has placed innovation and entrepreneurship at the heart of its strategy – from the development of plans for a new innovation campus at Grand Canal Quay, to the establishment of the University Bridge I and University Bridge Fund II.
The selection of an adjuvant that can help to stimulate robust mucosal immune responses for oral delivery will be a key task for the Lavelle lab during the course of the project. In the later stages of the project, the Lavelle lab will be responsible for the generation of data required for the filing of regulatory dossiers to proceed with clinical trials.
For further information, visit www.tcd.ie
Quoted Micro 14 November 2022
AQUIS STOCK EXCHANGE
First quarter trading at National Milk Records (NMRP) strengthened in all areas. Revenues increased by 4% to £5.98m. There was an 82% rise in genomic testing revenues to £151,000. Milk prices are expected to remain strong. The GenoCells services, which provide farmers with genomically driven individual animal cell count analysis, will be launched in the UK and US.
OTAQ (OTAQ) has switched from the standard list to the Access segment of Aquis. The share price has held steady at 5p. OTAQ raised £3.6m at 4p a share.
Shareholders have approved the reverse takeover of TECC Capital (TEC) by EDX Medical. The shares will recommence trading on 14 November.
Guanajuato Silver Company Ltd (GSVR) has discovered a new transverse vein at the El Cubo mine in Guanajuato, Mexico. This has been named the San Luis vein. The company has been reinterpreting previous data. This vein is likely to have a higher gold component than the primary structures. Vein widths are close to one metre or above.
Property investor Ace Liberty & Stone (ALSP) has exchanged contracts to acquire Loders Service Station in Dorset for £2.08m. There is a SPAR convenience store and BP filling station. The annual rental income is £168,000 and it increases to £185,000 in 2023.
Igraine (KING) says Conduit Pharmaceuticals is reversing into Nasdaq-listed Murphy Cannon Acquisition Corp. This will provide nearly $150m of funding for Conduit. Via a 2% stake in Excalibur Medicines, Igraine has an economic interest in AZD1656, which is a potential diabetes treatment, one of the assets of Conduit. Excalibur Medicines has exclusive rights to the patents on AZD1656. Fellow Aquis-quoted company Oscillate (MUSH) has a 25.7% stake in Igraine.
Goodbody Health Ltd (GDBY) says the full year outcome will be worse than expected. Third quarter figures showed a 6% decline in revenues to £9.29m due to reductions in Covid testing revenues, while margins declined. The loss nearly doubled to £1.67m. The cost base is being reduced.
Technology investor SuperSeed Capital Ltd (WWW) has made six investments since joining Aquis. The latest is Techsembly, a SaaS e-commerce platform offering payments technology to hotel operators. NAV is 95p a share.
Electric vehicle drivetrains developer Equipmake (EQIP) says 2021-22 revenues were better than expected at £3.7m. More of the revenues are coming from commercial projects. The loss has fallen to £4.3m.
Altona Rare Earths (ANR) is drawing down £150,000 in two tranches from Align Research Investments. The interest rate is 15% and there are also warrants equal to 150% of the loan value exercisable at 12p a share.
Gunsynd (GUN) investee company Rincon Resources says a preliminary report highlights similarities between its Pokali prospect and a nearby niobium rare earth discovery.
EPE Special Opportunities (EO.P) announced net assets of 239.2p a share at the end of October 2022, down from 242.3p a share the month before.
AQRU (AQRU) has linked up with accountancy firm Sampson Fielding to offer technology-led accountancy services for institutions holding digital assets and their auditors. The brand will be Daxiom.
AIM
PayPoint (PAY) is bidding for Appreciate (LAPP) in a deal that values the prepaid vouchers and Christmas savings group at £83m – based on a PayPoint share price of 580p. The offer is 33p in cash and 0.019 of a PayPoint share for each Appreciate share. A 0.8p a share dividend will also be paid to Appreciate shareholders. The PayPoint share price has fallen to 547p, so the bid is not worth quite as much now.
Motor dealer Vertu Motors (VTU) is in talks to acquire Helston Garages Group Ltd. This would be funded by debt. The controlling party of the company is the executors of the estates of former directors David Stanley Carr and Betty Vera Carr. Helston Garages is based in south west England and has 37 dealerships, plus two used car sites. Helston Garages had net cash was £10.8m at the end of 2021 and NAV was £136.2m.
Insolvency litigation financer Manolete Partners (MANO) is generating more cash, but a write down in the values of ongoing cases meant that reported revenues were lower. That is partly due to large case being lost and the general economic conditions. More importantly, realised revenues are increasing. The interim figures reflect cases that were taken on during a period of Covid restrictions and government assistance, when insolvencies were relatively low. Insolvency numbers are increasing so opportunities will increase.
Online home moving services provider Smoove (SMV) revealed a higher loss and cash outflow in the six months to September 2022. The benefits from investments in new products, such as Smoove Start, aimed at estate agents, and Smooth Complete, which is for conveyancing lawyers, won’t show through until next year. Costs are being reduced. Smoove has announced a tender offer of up to £5m, but that will still leave plenty of cash in the bank to fund the business as it moves towards breakeven.
Biome Technologies (BIOM) increased third quarter revenues by 77% to £1.9m. Both bioplastics and radio frequency divisions grew their contributions. Even so, Biome is being more cautious about pre-commercial customer projects and full year revenue expectations have been trimmed from £6.8m to £6.29m, which is still higher than the £5.73m generated in 2021. A full year loss of £1.1m is forecast.
PCF Group (PCF) has been unable to raise money or secure a strategic transaction, so PCF Bank is withdrawing from the UK banking market. The PCF board wants shareholder approval for the cancellation of the AIM quotation.
Mobile data computing services provider Touchstar (TST) has won a £1.5m contract with a petrochemical distribution client. There will be additional recurring revenues in future years. This underpins 2022 and 2023 pre-tax profit expectations of £400,000 and £700,000 respectively.
Poolbeg Pharma (POLB) has identified multiple novel drug targets for the treatment of respiratory syncytial virus. This has been achieved within eight months with its partner OneThree Biotech. This includes known drugs with phase 1 safety and efficacy data. The best candidates should be identified by the end of the year.
Beximco Pharmaceuticals Ltd (BXP) increased 2021-22 net sales from £251.4m to £309.7m with growth coming from domestic sales and exports. However, profit after tax fell from £26.6m to £24m. No revenues are anticipated from Covid vaccines in the near-term.
Construction claims and disputes consultancy Driver Group (DRV) made an underlying loss in the year to September 2022, but management believes that the Middle East and Asian operations should return to profitability this year. Europe and the Americas remain profitable.
MAIN MARKET
Made.com (MADE) has gone into administration and PwC is handling the administration. Next (NEXT) has acquired the brand and IP.
National World (NWOR) has invested $1.25m in social-first media company The News Movement. National World hopes that this will help to attract a younger audience to its publications.
Andrew Hore
